pathogenesis of asthma through cytokine production. This is supported by studies showing increased activation of T lymphocytes following allergen provocation [5, 6] , and by studies showing an association between activated T lymphocytes and severity of asthma [7] . Activated CD4 positive T helper (Th) lymphocytes are subdivided into two distinct phenotypes based on the cytokines they produce [8] . Th1 lymphocytes produce cytokines such as interferon-g (IFN-γ), interleukin (IL)-2 and IL-12, whereas Th2 lymphocytes produce cytokines such as IL-4, IL-5 and IL-13. Th1/Th2 counter-regulation has also been described, with each lymphocyte population capable of inhibiting and/or regulating the development and/or phenotype induced by the other [8] . Previous studies have demonstrated an imbalance of Th1/Th2 towards Th2 predominance, which is thought to underlie asthmatic responses [9] .
Recently, a third type of T cell phenotype has been identified. The regulatory T cell (Tregs) phenotype is mainly characterized by expression of forkhead box P3 (Foxp3) protein, and these Tregs are potent mediators of dominant self-tolerance [10] . Tregs have the potential to suppress both Th1-and Th2-induced inflammation [11, 12] . Activation and expansion of Tregs may be exploited for treatment of immunologic diseases such as allergic asthma [13] . Cytotoxic T-lymphocyte antigen 4 (CTLA4) is a homolog of CD28, which is expressed only on activated T cells, and binds to the accessory molecules B7-1 (CD80) and B7-2 (CD86) [14, 15] . Like CTLA4
CD25
+ T cells, Tregs also have the ability to down-regulate Th1 and Th2 responses though CTLA4 signaling [16] . It is well known that CTLA4 is expressed on both surface and cytoplasm in cells. The surface CTLA4 expressed on T cells have immunosuppressive effects [17, 18] . Surface CTLA4 also play a role in sequestration of B7 molecules without cytoplasmic CTLA4 and the sequestration is regulated by the levels of surface expression of CTLA4 [19] .
The present review discusses the correlation between chronic airway eosinophilic inflammations, asthmatic response and regulatory T cells in asthma.
Evaluation of airway inflammation and hyperresponsiveness
Airway inflammation is a major factor in the pathogenesis of asthma, as shown by the fact that inhaled corticosteroids (ICS) are the first choice of medications in patients with asthma. To understand the pathogenesis and mechanisms of asthmatic responses, the evaluation of airway inflammation is important. Many approaches are available to investigate airway inflammation. Induced sputum [20] , fraction expiratory nitrogen oxide (F E NO) [21, 22] , and exhaled breath condensate (EBC) [23, 24] are non-invasive techniques, whereas bronchial alveolar lavage fluid (BALF) [9, 25] , bronchial epithelial lining fluid (ELF) [26] and bronchial biopsy [27, 28] are more invasive but can provide additional information. The F E NO and EBC give us information from exhaled gases, but tell us nothing about airway cell differentiation, while BALF, ELF and biopsy use flexible endobronchoscopy. Among these examination techniques, the induced sputum technique is not only safe and easy to perform, it also enables us to obtain information about both cells and supernatants repeatedly [29] . The induced sputum technique also can assess the effectiveness of newly developed agents [30, 31] . The number of airway eosinophils in patients with mild asthma was significantly higher than non-asthmatic control subjects (control subjects) ( Figure 1A and 1B) [32] . The number of airway eosinophils was also increased in patients with asthma after allergen, but not methacholine (Mch) challenge ( Figure 1C ) [33] .
Evaluation of nonspecific AHR
The second major factor in the pathogenesis of asthma is AHR. There are two types of AHR. The first involves a nonspecific response to MCh, acetylcholine and histamine, and the other involves a specific response to antigens such as house dust mite, ragweed, and cat. [1, 34, 35] . MCh reveals the effects of bronchoconstriction via airway muscarinic receptors, and a decline of the forced expiratory volume in 1 second (FEV 1 ) is observed by spirometry after inhaled MCh challenge in asthma patients [34, 35] . Figure 2A shows the % changes in FEV 1 from baseline after 0.7% NaCl, and doubling doses of MCh (0.03 mg/mL to 32 mg/mL) in control subjects without history of asthma, patients with intermittent and persistent mild asthma, and patients with cough variant asthma (unpublished data). The MCh challenge tests were performed in accordance with previous studies [34, 35] . The severity of asthma was evaluated based on the Global Initiative for Asthma (GINA) guidelines [36] . The mean percentages of FEV 1 in all patients with asthma fell to under 80% of the baseline at MCh concentrations less than 8 mg/mL, although those in control subjects remained above 80% of baseline at MCh concentrations of 16 mg/mL. In patients with intermittent and persistent mild asthma, there was a significant negative correlation between airway inflammation (number of sputum eosinophils) and AHR (provocative concentration of MCh causing a 20% fall
Allergen challenge tests as human asthma attack models
Patients with atopic, but not non-atopic, mild asthma are divided into 2 phenotypes, namely isolated early responders (IER) and dual responders (DR) [1] . Figure 3 shows the changes in %FEV 1 from baseline in FEV 1 (PC 20 ) ( Figure 2B ) (unpublished data)). However, the airway inflammation as measured by proportion (%) of eosinophils in induced sputum was unchanged after MCh provocation in patients with asthma ( Figure 1C ) [33] . Fig. 1 . Induced sputum between asthmatics and control subjects, and sputum eosinophils after methacholine and allergen challenge tests Notes: A) The findings of induced sputum with May-Giemsa strain (× 200, PZ-9000®, Keyence co., Tokyo) after cytospin preparation. The sputa were obtained from a stable patient with asthma (32 years old, male, GINA step I) (top) and a control subject (34 years old, male, non-smoker). B) Comparison in the number of sputum eosinophils between stable mild asthma (n=16) and control subjects (n=12). The tests of inductions of sputum were performed after written consents in each subject at the Respiratory Disease Center, Kurume University School Hospital (A and B) (unpublished data). Data were expressed as mean (Standard error from mean, SEM). ** p<0.01 versus healthy subjects. C) Kinetics of number of sputum eosinophils after MCh and allergen challenge [34] . Data were expressed as mean (SEM). ** p<0.01 versus pre-challenge.
after inhaled allergen challenge test and the mean geometric PC 20 -MCh values pre and post inhaled allergen challenge tests (unpublished data) [38] . Early (EAR) and late asthmatic responses (LAR) occur after inhaled provocation of specific allergens in patients with atopic mild asthma [1, 37] . EAR is shown by the decline of FEV 1 with bronchoconstriction within 30 min after provocation of allergen, and the LAR is defined as bronchoconstriction with recruited airway inflammation 3 hrs after EAR ( Figure 3A) . The IER have only EAR, whereas the DR have both EAR and LAR [1] . The population of patients with atopic mild asthma is evenly divided between IER and DR [1] . The responses are reproduced just like human asthma attacks after inhaled provocation of allergen in asthmatics with DR ( Figure 1C and Figure 3A) . Interestingly, the AHR is exacerbated after allergen provocation, as the mean geometric PC 20 -MCh values are decreased after inhaled allergen challenge ( Figure 3A ). In accordance with these results, the first line of treatment should focus on prevention of provocation by allergens, rather than medicines, in patients with atopic asthma, when specific allergens associated with exacerbations of asthma are found [36] . For example, the efficacy of inhaled corticosteroids (ICS) [37] [38] [39] , the main management strategy for asthma, have been investigated using human allergen challenge models in DR ( Figure  3C and 3D) [37] . Pre-treatments with ICS, ciclesonide 40 and 80 μg/day, attenuate LAR ( Figure 3C ), and also attenuate allergen-induced airway eosinophilic inflammation when compared with placebo ( Figure 3D ) [37] . However, the effects of ciclesonide are not dose dependent.
Airway regulatory T cells (Tregs) in patients with asthma
The populations of cytotoxic T-lymphocyteassociated protein 4 (CTLA4) 20 -MCh values between IER and DR after allergen challenge (Unpublished data were obtained at McMaster University after written consents in each subject) [37] . The geometric PC 20 -MCh values with both IER and DR were significant deceased after allergen challenge. The areas under the curve (AUC) of LAR with DR was significantly greater than those with IER. ▲ p<0.05 between IER and DR. * p<0.05 between pre-and post-allergen challenge. B) Comparison of sputum inflammatory cell differentiations between IER and DR after allergen challenge [40] . Data were expressed as mean (SEM). Sputum total cell counts (TCC, ×10 6 cells/mL) with IER and DR were increased, but not significantly from pre-to 24hrs post-allergen challenge (both, p>0.05), and there was no significant difference in sputum TCC between IER and DR pre-and post-allergen challenge (p>0.05) (data not shown) [40] . * p<0.05 and ** p<0.01 versus pre-allergen challenge. C) Comparison of AUC of %changes in FEV 1 after allergen challenge among pre-treatments (7days) with ciclesonide 80 μg/day, ciclesonide 40 μg/day, and placebo [37] . There was no significant difference in the AUC between ciclesonide 80 μg/day and ciclesonide 40 μg/day. ▼p<0.05 versus placebo. D) Comparison of AUC of changes in number of sputum eosinophils after allergen challenge among pre-treatments (7days) with ciclesonide 80 μg/day, ciclesonide 40 μg/day, and placebo [37] . There was no significant difference in the number of sputum eosinophils between ciclesonide 80 μg/day and ciclesonide 40 μg/day. * p<0.05 and ** p<0.01 versus pre-allergen challenge. Abbreviations: DR, dual responders; EAR, early asthmatic response; FEV 1 , forced expiratory volume in 1 second; IER, isolated early responders; LAR, late asthmatic response; MCh, methacholine; PC 20 
Kinetics of Tregs after allergen challenge in adult atopic mild asthma
To investigate the kinetics of Tregs, allergen challenge tests were performed in adult atopic mild asthma with IER and DR [40] . The % Tregs (Foxp3 + /CD4 + cells) were significantly decreased in DR, but not IER, after allergen challenge ( Figure 5A ). The change in Tregs (delta Tregs) from pre-(0hr) to 24 post-allergen challenge (24hrs) was significantly associated with the maximum %fall in FEV 1 during LAR (from 3hrs to 7hrs after allergen challenge) in DR ( Figure 5B ). The magnitude of the decrease in Tregs induced by the allergen may affect the severity of LAR.
Our results [32, 40] suggest that airway Tregs may be decreased, and that the decreased Tregs may be associated with increased airway inflammation in asthma. This inflammation may contribute to bronchoconstriction. However, the mechanisms of the decrease in Tregs are still unclear.
Efficacy of ICS on airway Tregs in patients with asthma
A randomized double-blind, cross-over, placebo control trial investigated whether treatment with ICS (Fluticasone propionate, GSK, Japan) could increase the population of sputum CTLA4 + Tregs, decrease sputum eosinophils, and increase interleukin (IL)-10 ( Figure 6 ) [41] . The effect of ICS on Foxp3 + Tregs has not yet been investigated in patients with asthma.
Natural immunity and acquired immunity in asthma
Immune lymphoid cells 2 (ILC2) are well known as one of the inflammatory cell types in natural immunity [42, 43] . ILC2 may affect the molecular mechanisms of corticosteroid insensitivity in asthma [44] . ILC2, similar to Th2 cells, may play a role in allergic response, ILC1, like NK and Th1 cells, may play a role in autoimmune disorders, and ILC3, like Th17, may be associated with neutrophilic response in ac- 
Foxp3
+ Tregs in induced sputum and peripheral blood between patients with stable mild asthma and non-asthmatic subjects as controls [42] . Data were expressed as mean (SEM). * p<0.05 and ** p<0.01 versus controls. † p<0.05 and ‡ p<0.01 versus peripheral blood. B) The correlation between sputum %CTLA4
+ and Foxp3 (Figure 7 ) [45, 46] . However, Tregslike cells working in the innate immune system have not been found, whereas Tregs expressing Foxp3 + and CTLA4 + CD4 are able to modulate inflammation as an acquired immune response.
Conclusion
The interactions between airway inflammation and AHR in asthma were examined. ICS as anti-inflammatory agents are the first choice for management of asthma, but they are just controllers. Curing asthma is still difficult, although anti-IgE and anti-IL-5 therapies have shown results in severe asthma that are as good as other anti-allergic inflammatory agents [47] [48] [49] . Development of new treatment strategies utilizing Tregs could be useful in attenuating allergic reactions and achieving a cure for asthma. + Tregs after allergen challenge in stable atopic mild asthmatic with IER and DR [40] . The %Foxp3 + Tregs with DR were significantly lower than those with IER 24hrs post-allergen challenge (p<0.05). Data were expressed as mean ± SEM. B) The correlation between sputum %Tregs, sputum %eosinophils, and LAR (including unpublished data) [40] . The correlation (r) between delta %sputum Tregs (0-24hrs) and %maximal %fall in FEV 1 during LAR (3-7hrs) was 0.65 (p=0.0011). The correlation between delta %sputum eosinophils (0-24hrs) and %maximal %fall in FEV 1 during LAR (3-7hrs) was -0.52 (p=0.0150) (unpublished data). The correlation between delta % sputum Tregs (0-24hrs) and delta %sputum eosinophils (0-24hrs) was -0.59 (p=0.0047) (unpublished data). Data of DR and IER were expressed as closed and opened circles, respectively. Abbreviations: DR, dual responders; IER, isolated early responder; FEV 1 , forced expiratory volume in 1 second; Foxp3, forkhead box P3; LAR, late asthmatic response; NS, not significant; Tregs, regulatory T cells; SEM, standard error of the mean
Fig. 6. Sputum regulatory T cells in mild asthmatics after treatment with inhaled corticosteroids Notes: A) Comparison of changes in sputum %CTLA4
+ Tregs between ICS and placebo [41] . Data were expressed as mean (SEM). * p<0.05 versus pre-treatment. B) Comparison of changes in IL-10, TGF-β1 and IL-13 levels of sputum supernatants between ICS and placebo [41] . Data were expressed as mean (SEM). * p<0.05 versus pre-treatment Abbreviations: CTLA4, cytotoxic T-lymphocyte antigen 4; ICS, inhaled corticosteroids; IL, interleukin; SEM, standard error of the mean; TGF, Transforming growth factor; Tregs, regulatory T cells 
